Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomised phase II trial in patients with high risk GCT.
Primary objective:
- Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high
risk' GCT as compared to standard care
Secondary objectives:
- Determine the relapse free survival
- Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT